Article Text

Download PDFPDF

Price, pragmatism and ▼prasugrel

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

In October 2009, the National Institute for Health and Clinical Excellence (NICE) issued guidance on the use of ▼prasugrel (Efient) in patients with acute coronary syndrome undergoing percutaneous coronary intervention.1 This recommended prasugrel as a better option than clopidogrel in, for example, patients with ST-segment-elevation myocardial infarction or diabetes mellitus. Evidence of prasugrel's efficacy was based on one trial comparing it with …

View Full Text